申请人:BLUEPRINT MEDICINES CORPORATION
公开号:US10017512B2
公开(公告)日:2018-07-10
This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I):
本公开涉及对野生型 NTRK 及其抗性突变体有活性的 NTRK 抑制剂,如式 (I) 化合物: